01515 CR MEDICAL
- 4.270
- -0.050-1.16%
CR MEDICAL News
Independent Non-Executive Director Ting Yuk Wu Sold A Bunch Of Shares In China Resources Medical Holdings
Anyone interested in China Resources Medical Holdings Company Limited (HKG:1515) should probably be aware that the Independent Non-Executive Director, Ting Yuk Wu, recently divested HK$2.6m worth of s
Changes in Hong Kong stocks | China Resources Healthcare (01515) fell more than 5% in the afternoon and its Huaiyin Hospital ceased operations, which will have a certain impact on this year's results
China Resources Healthcare (01515) fell more than 5% in the afternoon. As of press release, it was down 5.12% to HK$4.26, with a turnover of HK$35.3716 million.
China Resources Healthcare (01515.HK) was reduced by 1 million shares by independent non-executive director Hu Dingxu
Gelonghui, May 20 | According to the latest equity disclosure data of the Stock Exchange, from May 16 to May 17, 2024, China Resources Medical (01515.HK) was reduced by independent non-executive director Hu Dingxu by a total of 1 million shares at an average price of HK$4.3473-4.409 per share on the market, involving about HK$4.384 million. After the holdings were reduced, the latest number of shares held by Hu Dingxu was 0 shares, and the shareholding ratio dropped from 0.08% to 0%.
China Resources Medical (01515.HK) appoints Chung Ming Fai as Company Secretary
Gelonghui, May 16, 丨 China Resources Medical (01515.HK) announced that Mr. Su Yaofeng has resigned as the company's company secretary and will no longer act as an authorized representative and agent for legal proceedings, effective from May 16, 2024. Mr. Chung Ming Fai has been appointed as company secretary, authorized representative and agent for legal proceedings with effect from May 16, 2024.
China Resources Medical to Shutdown Loss-Making Unit
China Resources Medical Holdings (HKG:1515) intends to shutdown loss-making unit Huai'an City Huaiyin Hospital and will seek regulatory approval to do so, according to a May. 10 filing with the Hong K
China Resources Medical (01515.HK): Plans to shut down Huaiyin Hospital business
Gelonghui, May 10, 丨 China Resources Medical (01515.HK) announced that Huaiyin Hospital's business situation continued to decline and fall into losses due to the Group's announcement of impairment relating to Huai'an Huaiyin Hospital Co., Ltd. (“Huaiyin Hospital”), such as the company's 2022 and 2023 annual reports and the gradual loss of medical staff mentioned in the announcement, as well as changes in the external environment such as regional medical insurance resources and competition in the same industry. Although the Group has actively implemented many initiatives such as talent recruitment, business transformation, organizational restructuring, and cost reduction and efficiency, it has not been able to reverse the operating conditions of Huaiyin Hospital. Through local medical treatment
Individual Investors Are China Resources Medical Holdings Company Limited's (HKG:1515) Biggest Owners and Were Rewarded After Market Cap Rose by HK$532m Last Week
Key Insights The considerable ownership by individual investors in China Resources Medical Holdings indicates that they collectively have a greater say in management and business strategy The top 6
China Resources Medical's 2023 Profit Slides
China Resources Medical Holdings (HKG:1515) reported a profit attributable to owners of 257.7 million yuan for 2023, compared with 265.9 million yuan in the previous year, according to a Thursday fili
華潤醫療：2023 年度報告
[Broker Focus] CMB International expects China's pharmaceutical industry to return to healthy growth this year
Jinwu Financial News | CMB International said that since the beginning of the year, the MSCI China Healthcare Index has fallen 22.7%, outperforming the MSCI China Index by 23.3%. Looking ahead to 2024, China's pharmaceutical industry is expected to return to healthy growth as industry regulation is normalized and the impact of the COVID-19 base gradually subsides. The bank continues to be optimistic about BeiGene (06160), Cinda Biotech (01801), Columbotai (06990), Giant Biotech (02367), Gushengtang (02273), and Mindray Healthcare (300760). Additionally, it is recommended to focus on high-dividend stocks with steady performance, such as Regal Healthcare
CICC: Maintaining China Resources Healthcare's (01515) “Outperform the Industry” Rating Target Price of HK$5.6
The Zhitong Finance App learned that CICC released a research report stating that it maintained China Resources Healthcare's (01515) “outperforming the industry” rating and maintained 2024/2025 net profit of RMB551/715 billion, an increase of 113.8%/29.8% over the previous year, with a target price of HK$5.6. The company announced its 2023 results: revenue of RMB 10.108 billion, up 27.9% year on year; net profit to mother of RMB 258 million, a decrease of 3.1% year on year, in line with the forecast. CICC's main views are as follows: further expansion of the hospital network layout, hospital industry
CR MEDICAL To Go Ex-Dividend On June 7th, 2024 With 0.0661 HKD Dividend Per Share
March 20th - $CR MEDICAL(01515.HK)$ is trading ex-dividend on June 7th, 2024. Shareholders of record on June 11th, 2024 will receive 0.0661 HKD dividend per share on July 19th, 2024. The ex-divide
China Resources Medical will pay a final dividend of $0.06 per share on July 19
China Resources Medical (01515) announced that it will pay a final dividend of RMB 0.06 per share for the year ended December 31, 2023 on July 19, 2024.
China Resources Healthcare (01515) will pay a final dividend of $0.06 per share on July 19
According to Zhitong Finance App, China Resources Healthcare (01515) announced that it will pay a final dividend of RMB 0.06 per share for the year ended December 31, 2023 on July 19, 2024.
China Resources Healthcare (01515) announced annual results, with shareholders' share profit of 258 million yuan
China Resources Healthcare (01515) announced its annual results for the year ended December 31, 2023. The group reaped benefits, people...
CR MEDICAL: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
China Resources Medical Holdings (HKG:1515) Sheds HK$726m, Company Earnings and Investor Returns Have Been Trending Downwards for Past Year
Passive investing in an index fund is a good way to ensure your own returns roughly match the overall market. While individual stocks can be big winners, plenty more fail to generate satisfactory ret
Changes in Hong Kong stocks | China Resources Healthcare (01515) fell by more than 5% and expected annual profit to drop to about 250 million yuan
China Resources Healthcare (01515) fell more than 5% in early trading. As of press release, it was down 4.75% to HK$4.01, with a turnover of HK$29.59,900.
Changes in Hong Kong stocks | China Resources Healthcare (01515) opened nearly 8% lower after the earnings alert and expected annual profit to fall to about 250 million yuan
The Zhitong Finance App learned that China Resources Healthcare (01515) opened nearly 8% lower after the announcement. As of press release, it fell 7.78% to HK$4.15, with a turnover of HK$830,000. According to the news, China Resources Medical issued an announcement. Based on currently available data and a preliminary assessment of the group, it is estimated that the net profit for the year ending December last year is about 250 million yuan, down from the stated profit of about 270 million yuan for the same period in 2022. According to the announcement, the changes in the Group's performance during the reporting period were mainly affected by two events, namely: acquisitions during the reporting period; and the Group's calculation of Huai'an Huaiyin Medical
China Resources Medical (01515) Fa Ying Guang expects profit attributable to parent company owners to drop to about 250 million yuan in 2023
China Resources Medical (01515) announced that the group expects the parent company's owner's profit to be about RMB 2 in 2023...
Analysis
Price Target
No Data
